Medical and management approaches to the examination of hereditary cancer syndrome patients and their relatives

Cover Page

Cite item

Full Text

Abstract

Introduction. Genetic testing has become the part of the practice of providing specialized cancer care. This allows not only detecting the further tactics for patient management, but also identifying a risk group for the occurrence of malignant neoplasms (MNP). However, there are still no algorithms for dispensary monitoring of healthy carriers of mutations, which determined the relevance of our study.

The purpose of the study was to propose an organizational model for the work of the office of hereditary tumor pathology (HTP) based on the analysis of our own experience in identifying patients with hereditary oncological syndromes and their relatives as potent carriers of mutations associated with an increased risk of occurring MNP.

Materials and methods. Genetic testing was carried out in two thousand two hundred seventy six patients (residents of Moscow) with breast, gastrointestinal tract, and ovarian cancer.

Results. 714 patients out of 2276 MNP patients had mutations associated with an increased risk of developing cancer. Further, 277 relatives of these patients were invited, and mutations were detected in 143 (51.7%). Based on these data, an management model of the HTP office was proposed as part of the Outpatient Oncology Center (OOC), and the need for specialists to work in the HTP office per 100 thousand people was determined — 0.06 oncologist’s rate, 0.03 doctor’s rate-genetics and 0.03 psychologist rates.

Limitations. This study did not include patients who did not meet the selection criteria, as well as persons under 18 years of age or who isn’t resident of Moscow.

Conclusion. The introduction of genetic testing of patients’ relatives into practice will allow forming risk groups for subsequent dispensary observation, early detection of tumor and precancerous pathology.

Compliance with ethical standards. The study program was approved by the Moscow City Independent Ethical Committee (protocol No. 69 dated 10/13/2020).

Contribution of the authors:
Byakhova M.M. — research concept and design, writing the text, compilation of the list of literature;
Parts S.A. — research concept and design, writing the text, statistical data processing, editing, compilation of the list of literature;
Semenova A.B. — collection and processing of material;
Kuzmina E.S. — collection and processing of material, compilation of the list of literature, editing;
Didenko V.V. — collection and processing of material;
Galkin V.N. — collection and processing of material, editing;
Gadzhieva S.M. — statistical data processing, editing.
All authors are responsible for the integrity of all parts of the manuscript and approval of the manuscript final version.

Acknowledgments. The study was conducted at the expense of a grant from the Department of Health of the City of Moscow (agreement on the provision of a grant in the form of a subsidy from the budget of the city of Moscow GKOB No. 1 1022/2 dated 12/24/2020).

Conflict of interest. The authors declare no conflict of interest.

Received: August 7, 2023
Accepted: October 11, 2023
Published: December 23, 2023

About the authors

Maria M. Byakhova

Moscow City Oncological Hospital No.1, Moscow Healthcare Department

Author for correspondence.
Email: biakhovamm@mail.ru
ORCID iD: 0000-0002-5296-0068

MD, PhD, DSci., Head of the Genetics Laboratory of Center for Pathological Anatomical Diagnostics and Molecular Genetics of the Moscow State Budgetary Healthcare Institution Moscow City Oncological Hospital No. 1, Moscow Healthcare Department, Moscow, 117152, Russian Federation.

e-mail: biakhovamm@mail.ru

 

Russian Federation

Sergey A. Parts

Moscow City Oncological Hospital No.1, Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0009-0003-9954-4584
Russian Federation

Anna B. Semenova

Moscow City Oncological Hospital No.1, Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0002-8433-0837
Russian Federation

Evgenia S. Kuzmina

Moscow City Oncological Hospital No.1, Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0009-0007-2856-5176
Russian Federation

Vera V. Didenko

Moscow City Oncological Hospital No.1, Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0001-9068-1273
Russian Federation

Vsevolod N. Galkin

Moscow City Oncological Hospital No.1, Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0002-6619-6179
Russian Federation

Saida M. Gadzhieva

Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0009-0008-3455-493X
Russian Federation

References

  1. Baranova E.E., Bodunova N.A., Vorontsova M.V., Zakharova G.S., Makarova M.V., Rumyantsev P.O. Hereditary cancer syndromes: a modern paradigm. Problemy endokrinologii. 2020; 66(4): 24–34. https://doi.org/10.14341/probl12366 https://elibrary.ru/sxayzn (in Russian)
  2. Wilson J.M.G., Jungner G. Principles and Practice of Screening for Disease. Geneva; 1968.
  3. Sultanbaev A.V., Nasretdinov A.F., Galeev M.G., Men’shikov K.V., Musin Sh.I., Sultanbaeva N.I., et al. Breast cancer screening in germline mutation carriers. A literature review. Opukholi zhenskoy reproduktivnoy sistemy. 2023; 19(2): 16–24. https://doi.org/10.17650/1994-4098-2023-19-2-16-24 (in Russian)
  4. Semenova A.B., Byakhova M.M., Galkin V.N., Parts S.A., Makarova M.V., Nemtsova M.V., et al. Capabilities of molecular genetic methods for effective hereditary cancers detection in individuals with high cancer risk factors. Zdorov’e megapolisa. 2023; 4(2): 30–40. https://clck.ru/37BCRC https://elibrary.ru/kvcmae (in Russian)
  5. Kaprin A.D., Starinskiy V.V., Shakhzadova G.V. Malignant Neoplasms in Russia in 2021 (Morbidity and Mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’)]. Moscow; 2022. (in Russian)
  6. Merabishvili V.M. Survival of Cancer Patients [Vyzhivaemost’ onkologicheskikh bol’nykh]. St. Petersburg; 2006. (in Russian)
  7. IARC. Cancer tomorrow. Estimated number of new cases from 2020 to 2040, Both sexes, age [0–85+]. Available at: https://gco.iarc.fr/tomorrow/en/dataviz/isotype
  8. Collins J.M., Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. Breast J. 2020; 26(8): 152–7. https://doi.org/10.1111/tbj.13970
  9. Lei H., Zhang M., Zhang L., Hemminki K., Wang X.J., Chen T. Overview on population screening for carriers with germline BRCA mutation in China. Front. Oncol. 2022; 12: 1002360. https://doi.org/10.3389/fonc.2022.1002360
  10. Lubinski J. Breast cancer genetics: 20 years later. Clin. Genet. 2014; 85(1): 5–6. https://doi.org/10.1111/cge.12293
  11. Lieberman S., Lahad A., Tomer A., Koka S., BenUziyahu M., Raz A., et al. Familial communication and cascade testing among relatives of BRCA population screening participants. Genet. Med. 2018; 20(11): 1446–54. https://doi.org/10.1038/gim.2018.26
  12. Lee J., Ham J.Y., Park H.Y., Jung J.H., Kim W.W., Kang B., et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci. Rep. 2022; 12(1): 1842. https://doi.org/10.1038/s41598-022-05931-3
  13. Finlay E., Stopfer J.E., Burlingame E., Evans K.G., Nathanson K.L., Weber B.L., et al. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet. Test. 2008; 12(1): 81–91. https://doi.org/10.1089/gte.2007.0037
  14. MacDonald D.J., Sarna L., van Servellen G., Bastani R., Giger J.N., Weitzel J.N. Selection of family members for communication of cancer risk and barriers to this communication before and after genetic cancer risk assessment. Genet. Med. 2007; 9(5): 275–82. https://doi.org/10.1097/GIM.0b013e31804ec075
  15. Cheng X., Gu Z., Sun X., Zhuang Z. Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing. Transl. Cancer Res. 2019; 8(8): 2893–905. https://doi.org/10.21037/tcr.2019.11.43

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2023 Byakhova M.M., Parts S.A., Semenova A.B., Kuzmina E.S., Didenko V.V., Galkin V.N., Gadzhieva S.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС77-50668 от 13.07.2012 г.